What Is Pramiracetam?
Pramiracetam is a synthetic nootropic compound in the racetam family. Chemically, it is a lipophilic derivative of piracetam, and it was developed to produce cognitive effects at substantially lower milligram doses than the parent compound. The substance is also known by the research code CI-879 and has been marketed in some countries under names including Pramistar, Remen, and Neupramir. Its history is associated with European pharmaceutical development and Italian clinical use, particularly through the Pramistar brand, although the compound itself is generally described in the pharmacology literature as having been developed from the piracetam series by pharmaceutical researchers rather than as a traditional Italian medicine.
Pramiracetam is frequently advertised as being up to 30 times more potent than piracetam. This comparison should be interpreted cautiously: it is primarily a dose-equivalence claim based on experimental and commercial descriptions, not a universally accepted clinical measurement. Potency by milligram does not establish superior overall effectiveness, safety, or therapeutic value. Human trials have been relatively small and dated, and much of the mechanistic literature comes from animal or ex vivo studies. Unlike an approved cognitive medication, pramiracetam does not have a well-established evidence-based dosing standard for healthy adults.
The compound is of interest because racetams may influence neuronal membrane function, cholinergic signaling, and plasticity-related processes without acting as classic acetylcholinesterase inhibitors or direct stimulants. Pramiracetam has received particular attention for effects on high-affinity choline uptake, commonly abbreviated HACU, in the hippocampus. HACU is an important step in supplying choline for acetylcholine synthesis, and hippocampal cholinergic activity is closely associated with attention, encoding, and memory. These observations have led to interest in pramiracetam for memory disorders, age-associated cognitive decline, traumatic brain injury, and experimental amnesia.
Nevertheless, the distinction between a plausible mechanism and a demonstrated clinical benefit is important. Evidence does not establish that pramiracetam prevents dementia, reverses Alzheimer's disease, reliably improves intelligence, or produces durable benefits in healthy people. Product quality is also variable because many preparations are sold through supplement or research-chemical channels rather than regulated pharmaceutical systems.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders
Malykh, A. G., Sadaie, M. R., et al., 2010, Drugs - Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
Waegemans, T., Wilsher, C. R., Danniau, A., et al., 2002, Dementia and Geriatric Cognitive Disorders - Piracetam: a review of pharmacological properties and clinical uses
Winblad, B., 2005, CNS Drug Reviews - Piracetam: novelty in a unique mode of action
Müller, W. E., Eckert, G. P., Eckert, A., et al., 1997, Pharmacopsychiatry